

Proteomics: A Strategy for Translating Discoveries to the Cancer Clinic

<http://www.bio2007.org/program/sessiondate.asp?sCrit=Karger&sField=Name>

Track: Bench to Products
Monday, May 07, 2007
4:00 - 5:30 PM
Room Number: 258 B

Implemented in research laboratories across the globe, proteomic technologies have provided a wealth of information on the mechanisms underlying cancer. This session outlines a strategy for the advancement of clinical proteomic technologies that perform consistently across platforms, instruments and laboratories to facilitate biomarker discovery.

Objectives:

- Identify the major instruments and technologies used in proteomic research and clinical proteomic applications, including descriptions of their depth of coverage, throughput and accuracy for protein and peptide identifications; their utility in discovery-related research and clinical application; and their putative roles in diagnosis and therapeutic monitoring.
- Identify cellular and molecular pathways linked to tumorigenesis, and describe proteomic alterations that may reflect the onset of these pathways and be measured within the serum/plasma proteome.
- Describe and compare proteomic data representation, including qualitative measurements from technologies such as LC-MS/MS and quantitative.

Chair

Henry Rodriguez, PhD, MBA, Director, Clinical Proteomic Technologies for Cancer, National Cancer Institute

Speakers

Amanda Paulovich, MD, PhD, Director, Early Detection Initiative, Fred Hutchinson Cancer Research Center

Steven A. Carr, PhD, Director, Proteomics, Broad Institute of Harvard and MIT

Fred E. Regnier, PhD, J.H. Law Distinguished Professor, Purdue University

Barry Karger, PhD, Director, The Barnett Institute, Northeastern University